Mining the Hidden Gems in Unstructured EMR Data
This article was originally published in BioPharma Dive. Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR data is the unsung hero of most queries. Whether a manufacturer is struggling to find a niche patient population, conduct unbiased outcomes research, or generate persuasive […]
How Unstructured EMR Data Helps Pharma Find Patients
As therapies have become more complex, pharma companies are now challenged to achieve precision targeting within a much tighter timeframe. While claims data is readily available, one of its key limitations is the lack of timeliness. Many manufacturers now rely on specialized lab data—from imaging results to genetic testing and genomics—to identify eligible patients and […]
Mapping the Patient Journey: Six Commercial Use Cases for RWD
For years, pharma commercialization strategies focused only on traditional market access data: payer policies and restrictions. While payer coverage is still essential information, this single-source approach cannot help manufacturers identify the many barriers to access. In the path to treatment, there are so many hurdles that can stand in the way of a patient receiving […]
Harnessing Lab Data to Speed Time to Treatment
In recent years, pharma companies have begun to embrace lab data as a richly rewarding dataset for a whole host of purposes, including trial enrollment and site identification, patient monitoring and disease progression, and commercial targeting and market access insights. Along with test orders, values, and results, deidentified lab data includes a wealth of information, […]
From Integration to AI: The Data-Driven Future of Market Access
This article was originally published in Drug Channels. In a competitive market, pharma companies are increasingly relying on various datasets to drive their decision-making. With so many disparate sources, however, data standardization presents a challenge, especially for companies eager to use predictive analytics tools. In a recent survey of 125 pharma executives, nearly half cited data integration […]
Evaluating Payer Impact on Utilization with Claims and Coverage Data
To fully understand how payers impact patient access, pharma companies should be evaluating payers using multiple datasets, including both coverage/restriction data and claims data. While payer policies indicate how payers plan to manage a product or service, medical and pharmacy claims reveal how payers actually manage that product in reality. Taken together, claims and coverage […]
Using De-Identified Lab Data to Find Patients, Target Physicians and Expedite Treatment
Lab data has become an increasingly essential dataset for pharmaceutical companies at all stages of the product life cycle. A key use case for our MMIT clients is using lab data for commercial targeting. Since lab tests often represent one of the earliest data points in a patient’s diagnostic journey, pharma companies are using lab […]
Open vs. Closed Claims: Unlocking Opportunities for Healthcare Analytics
In the complex healthcare analytics landscape, understanding the nuances of open and closed claims is critical for researchers and analysts. Open and closed claims each offer unique insights into the patient journey. Open claims, sourced from various clearinghouses and warehouses across the U.S., present a vast collection of data, while closed claims, adjudicated by insurers, […]
Acing Market Access: Six Steps to Take Before Launch
Our first post in this series discussed how early market access research, conducted in the 12-18 months before launch, helps pharma companies identify differentiators and establish accurate expectations. As your organization moves closer to launch, your market access team will need to establish a commercially focused definition for your patient population. You’ll need to identify […]
Why Pharma Should Invest in Evidence-Based Physician Education
This article was originally published in BioPharma Dive. For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical. Today’s molecular-targeted therapies […]